Abbott Laboratories (ABT), VIVUS, Inc. (VVUS) – It’s Official: Obesity Is a Disease

According to the American Medical Association, obesity is now officially a disease.

A highly preventable disease, but a disease nonetheless.

I think that’s probably the right call. For many people, lung cancer is highly preventable — just don’t smoke — but it would be weird not to call lung cancer a disease.

The decision wasn’t without debate, though. In fact, the AMA’s Council on Science and Public Health actually recommended against calling obesity a disease. The main issue revolves around using body mass index, or BMI, as a measure for obesity. A 5’11” man who weighs 215 pounds is technically obese, but he may be fairly healthy and probably doesn’t need to be treated aggressively. There was also a worry that calling obesity a disease might let people off the hook in trying to prevent it in the first place.

Ultimately, the AMA’s House of Delegates ignored the council’s recommendation, voting in favor of a resolution to recognize obesity as a disease.

Great news for these companies
In the past, there’s been a distinct lack of interest in treating obesity. Doctors felt that it was mostly an aesthetic issue, so drugs to treat obesity had to be very safe. The severity of the disease is always a consideration in the acceptability of how severe side effects can be.

More recently, it’s become clear that obesity is a risk factor for other issues including type 2 diabetes and high blood pressure, making prevention and treatment a higher priority.

Abbott Laboratories (NYSE:ABT)

Unfortunately, having Wyeth’s Fen-Phen and Abbott Laboratories (NYSE:ABT)‘s Meridia pulled off the market because of side effect issues made many doctors wary of treatments. VIVUS, Inc. (NASDAQ:VVUS) got off to a very slow start, selling just $4.1 million of its obesity drug Qsymia in the first quarter, its second full quarter on the market.

The AMA’s decision should shed light on the issue, stressing treatment. But I continue to think it’s going to take time before doctors have enough experience prescribing Qsymia and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Eisai’s Belviq that they’re prescribing them to a majority of their obese patients. Clinical trial data is nice, but there’s no substitute for real-life experience on a few select patients.

Perhaps more importantly, the AMA’s decision could affect reimbursement for the drugs. VIVUS, Inc. (NASDAQ:VVUS) and Eisai are slowly gaining coverage from private insurersm, and an endorsement by the AMA certainly won’t hurt their efforts. VIVUS, Inc. (NASDAQ:VVUS) is shooting for 50% coverage of people covered by private insurance by the end of the year  The AMA’s endorsement may also affect government coverage. A bill was recently introduced into Congress that would provide coverage of obesity drugs by Medicare.

Orexigen Therapeutics, Inc. (NASDAQ:OREX) , the third player whose obesity drug could be approved next year, might be hitting the market at the perfect time, just as all the kinks are worked out. And if its drug Contrave is approved, it’ll be the only one to have shown that it doesn’t cause cardiovascular problems.

The article It’s Official: Obesity Is a Disease originally appeared on Fool.com.

Fool contributor Brian Orelli plans to go for a run after finishing this article. He has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Most Expensive Animals in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!